Search - tctmd.com

Displaying 221 - 240 of 631

Sort: Relevancy | Date

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

News Daily News

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Michael O'Riordan

February 16, 2023

News Daily News

Only Half of Revascularized PAD Patients Receive GDMT

L.A. McKeown

February 14, 2023

News Daily News

Maternal CV Risk After Adverse Pregnancy Outcome Can Last Over 40 Years

L.A. McKeown

February 13, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Daily News

UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy

Michael O'Riordan

January 20, 2023

News Daily News

Zero CAC? LDL Cholesterol May Not Predict MI, ASCVD

Yael L. Maxwell

January 17, 2023

News Opinion CV Team Dispatch

January 2023 News Roundup

L.A. McKeown

January 16, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

L.A. McKeown

January 13, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Daily News

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Michael O'Riordan

December 14, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

A Simple Nudge Moves the Needle on Statin Prescribing

Michael O'Riordan

December 02, 2022

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

Todd Neale

November 06, 2022

Advertisement

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Only Half of Revascularized PAD Patients Receive GDMT

Maternal CV Risk After Adverse Pregnancy Outcome Can Last Over 40 Years

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy

Zero CAC? LDL Cholesterol May Not Predict MI, ASCVD

January 2023 News Roundup

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

A Simple Nudge Moves the Needle on Statin Prescribing

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content